Tiotropium/olodaterol in COPD: Disadvantages in some patients, advantages in others

(Institute for Quality and Efficiency in Health Care) For most patients, the fixed-dose combination has neither advantages nor disadvantages. More flare-ups occur in higher severity grades. Women with rare flare-ups have advantages.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news

Related Links:

Condition:   Emphysema or COPD Intervention:   Other: NA: intervention is not part of the study Sponsor:   University Medical Center Groningen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Obstructive Pulmonary Disease (COPD) Interventions:   Other: Single then dual task situation;   Other: Dual then single task situation Sponsors:   Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer;   Université de Toulon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
By MATTHEW HOLT I’ve been driven steadily nuts by a series of recent articles that are sort of describing what’s happening in health tech or (because the term won’t die) digital health, so I thought it was time for the definitive explanation. Yeah, yeah, humility ain’t my strong suit. It won’t have escaped your attention that, after five years during which Castlight Health more or less single-handedly killed the IPO market for new health tech companies, suddenly in the middle of July 2019 we have three digital health companies going public. While Livongo, (FD-a THCB sponsor) Phreesia a...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Technology Matthew Holt Digital health investing Health Catalyst IPO Livongo Phreesia venture capital Source Type: blogs
Source: International Journal of COPD - Category: Respiratory Medicine Tags: Clinical Pharmacology: Advances and Applications Source Type: research
The objective of this study was to evaluate the bronchodilator efficacy of a single-dose 12/400-µg formoterol plus budesonide combination as a dry powder for inhalation delivered by Discair® in adult patients with moderate-to-severe, stable, chronic obstructive pulmonary disease.MethodsA total of 33 male patients with moderate-to-severe, chronic obstructive pulmonary disease were included in this single-arm, open-label, phase IV trial. The primary efficacy parameters were the average maximum change in forced expiratory volume in 1  s (FEV1, in L) and time to maximum FEV1 response. Absolute and percent change...
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
Nontypeable Haemophilus influenzae (NTHi) is a pathogen known for being a frequent cause of acute otitis media in children and respiratory tract infections in adults with chronic obstructive pulmonary disease. In the present study, a vaccine antigen based on the fusion of two known NTHi adhesive proteins, protein E (PE) and a pilin subunit (PilA), was developed. The quality of the combined antigen was investigated through functional, biophysical, and structural analyses. It was shown that the PE and PilA individual structures are not modified in the PE-PilA fusion and that PE-PilA assembles as a dimer in solution, reflecti...
Source: Infection and Immunity - Category: Infectious Diseases Authors: Tags: Microbial Immunity and Vaccines Source Type: research
Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Part A: RPL554;   Drug: Part B: RPL554;   Drug: Placebos Sponsors:   Verona Pharma plc;   Iqvia Pty Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COPD Interventions:   Dietary Supplement: fortisip compact protein;   Dietary Supplement: preOp Sponsors:   University College, London;   Nutricia, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Part A: RPL554;   Drug: Part B: RPL554;   Drug: Placebos Sponsors:   Verona Pharma plc;   Iqvia Pty Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COPD Interventions:   Dietary Supplement: fortisip compact protein;   Dietary Supplement: preOp Sponsors:   University College, London;   Nutricia, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Obstructive Pulmonary | Health | Health Management | International Medicine & Public Health | Spiriva | Tiotropium | Women